Nuclea obtains $1 million in equity funding round

02/22/2013 | American City Business Journals

Nuclea Biotechnologies has secured $1 million in a round of equity financing from 10 investors. The Pittsfield, Mass.-based company focuses on the commercialization of cancer and diabetes diagnostic tests, including a blood-based assay that CEO Patrick Muraca said has been clinically tested for monitoring prostate cancer and other uses.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA